Buprenorphine (BUP) Rapid Test Device

Buprenorphine, abbreviated as BUP in drug testing, is an opioid medicine available by prescription. It may be used under medical supervision for opioid dependence and severe pain. In drug testing, BUP is commonly used as the short code for buprenorphine screening. A BUP urine test helps detect buprenorphine or related markers in urine specimens, which is useful in clinical toxicology, medication compliance monitoring, rehabilitation programs, and professional drug screening settings.

The Buprenorphine (BUP) Rapid Test Device is used for preliminary qualitative screening of buprenorphine in urine. It helps trained professionals identify urine specimens that may require review, documentation, or confirmatory testing.

Applications

• Drug of abuse screening programs
• Clinical toxicology laboratories
• Opioid treatment monitoring workflows
• Rehabilitation and recovery centers
• Pain management monitoring programs
• Occupational health screening
• Emergency department screening support
• Institutional and compliance-based urine testing

• Buprenorphine has legitimate medical uses, but it is also a controlled opioid medicine in many countries. Monitoring may be required in opioid treatment programs, pain management settings, rehabilitation centers, and clinical drug monitoring workflows.
• Urine toxicology testing for people taking buprenorphine may support appropriate interpretation in treatment settings, especially when medication compliance or drug monitoring is required.
• The Buprenorphine BUP Rapid Test Device supports fast screening and helps laboratories maintain organized urine drug screening workflows. Professional interpretation remains important because medication history, prescription status, specimen integrity, assay limitations, and confirmatory testing all influence final reporting.

The Buprenorphine (BUP) Rapid Test Device uses a rapid test method for urine specimens. It is designed for qualitative detection at a 300 ng/mL cut-off. Urine is widely used in drug screening because it is practical, non-invasive, and suitable for detecting many drugs and metabolites in professional testing environments.

Benefits

• Urine-based rapid screening format
• 300 ng/mL buprenorphine cut-off
• Designed for BUP drug screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for toxicology and compliance workflows
• Helps support opioid treatment monitoring programs
• Applicable for hospitals, clinics, laboratories, and institutions
• Developed for international drug screening requirements

The Buprenorphine (BUP) Rapid Test Device is designed for urine specimens. Urine is commonly used in toxicology screening because it is convenient for drug and metabolite detection workflows.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Buprenorphine (BUP) Rapid Test Device by LARKSOIS Pharma has a stated cut-off of 300 ng/mL. This means the device is designed to screen for buprenorphine in urine at or above the validated threshold. LARKSOIS Pharma should mention the exact cut-off and performance details according to the final product insert, technical file, and regulatory documentation.

Steps

• Collect urine specimen using proper collection procedure
• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Use the device according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read results only within the recommended time window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Buprenorphine (BUP) Rapid Test Device.

Positive

A positive result suggests that buprenorphine may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary unless confirmed by an appropriate laboratory method.

Negative

A negative result suggests that buprenorphine was not detected or was below the test cut-off at the time of testing. A negative result does not replace clinical or professional judgment.

Invalid

If the control indicator does not appear, the result is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Protect from direct sunlight, moisture, contamination, and unsuitable temperatures
• Use urine specimens only
• Do not use expired test devices
• Do not use damaged or opened pouches
• Follow the product insert carefully
• Use clean sample collection procedures
• Interpret results within the stated reading window
• Treat all urine samples as potentially biohazardous
• Dispose of used materials according to laboratory safety rules

Instructions

• For professional in vitro diagnostic use only
• Not intended for home use
• Not intended to diagnose substance use disorder
• Not intended to diagnose overdose or intoxication
• Positive results are preliminary unless confirmed
• Negative results do not replace clinical judgment
• Confirmatory testing is recommended where results affect medical, legal, workplace, or institutional decisions
• Buprenorphine use and prescription rules vary by country
• Follow local clinical, workplace, forensic, and regulatory guidelines

LARKSOIS Pharma focuses on reliable diagnostic solutions for global healthcare providers, laboratories, distributors, and institutional screening programs. The Buprenorphine (BUP) Rapid Test Device is developed for professional environments where fast, clear, and dependable screening support is important.

Advantages

• Urine-based rapid screening format
• 300 ng/mL buprenorphine cut-off
• Designed for BUP drug screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for toxicology and compliance workflows
• Helps support opioid treatment monitoring programs
• Applicable for hospitals, clinics, laboratories, and institutions
• Developed for international drug screening requirements